Antibody-Drug Conjugates 2012

Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs.  These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical candidates.